Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Javle, M Borbath, I Clarke, S Hitre, E Louver, C Macarulla, T Oh, D Spratlin, J Weiss, K
Javle, M
Borbath, I
Clarke, S
Hitre, E
Louver, C
Macarulla, T
Oh, D
Spratlin, J
Weiss, K
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Javle M, Borbath I, Clarke S, Hitre E, Louvet C, Macarulla T, et al. P-225 Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. Ann Oncol. 2019;30(Supplement_4):62.